EBV-driven lymphoid neoplasms associated with pediatric ALL
maintenance therapy

J 2023

EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy

ELITZUR, Sarah, Ajay VORA, Birgit BURKHARDT, Hiroto INABA, Andishe ATTARBASCHI et. al.

Základní údaje

Originální název

EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy

Autoři

ELITZUR, Sarah (garant), Ajay VORA, Birgit BURKHARDT, Hiroto INABA, Andishe ATTARBASCHI, Andre BARUCHEL, Gabriele ESCHERICH, Brenda GIBSON, Hsi-Che LIU, Mignon LOH, V Moorman ANTHONY, Anja MOERICKE, Rob PIETERS, Anne UYTTEBROECK, Susan BAIRD, Jack BARTRAM, Shlomit BARZILAI-BIRENBOIM, Sandeep BATRA, Miriam BEN-HAROSH, Yves BERTRAND, Trudy BUITENKAMP, Kenneth CALDWELL, Ricardo DRUT, Ashley V GEERLINKS, Gil GILAD, John GRAINGER, Stephanie HAOUY, Nicholas HEANEY, Mary HUANG, Danielle INGHAM, Zdenka KŘENOVÁ (203 Česká republika, domácí), Michaela KUHLEN, Thomas LEHRNBECHER, Atsushi MANABE, Felix NIGGLI, Claudia PARIS, Shoshana REVEL-VILK, Pierre ROHRLICH, Mohamad G SINNO, Tomasz SZCZEPANSKI, Melanie TAMESBERGER, Rajasekharan WARRIER, Matthias WOLFL, Ronit NIREL, Shai IZRAELI, Arndt BORKHARDT a Kjeld SCHMIEGELOW

Vydání

Blood, Washington DC, USA, American Society of Hematology, 2023, 0006-4971

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 20.300 v roce 2022

Kód RIV

RIV/00216224:14110/23:00131032

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1182/blood.2022016975

UT WoS

000968991200001

Klíčová slova anglicky

EBV-driven lymphoid neoplasms; pediatric ALL; maintenance therapy

Štítky

14110317, 14110321, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 2. 2024 09:44, Mgr. Tereza Miškechová

Anotace

V originále

The development of a second malignancy after the diagnosis of childhood acute lymphoblastic leukemia (ALL) is a rare event. Certain second malignancies have been linked with specific elements of leukemia therapy, yet the etiology of most second neoplasms remains obscure and their optimal management strategies are unclear. This is a first comprehensive report of non-Hodgkin lymphomas (NHLs) following pediatric ALL therapy, excluding stem-cell transplantation. We analyzed data of patients who developed NHL following ALL diagnosis and were enrolled in 12 collaborative pediatric ALL trials between 1980-2018. Eighty-five patients developed NHL, with mature B-cell lymphoproliferations as the dominant subtype (56 of 85 cases). Forty-six of these 56 cases (82%) occurred during or within 6 months of maintenance therapy. The majority exhibited histopathological characteristics associated with immunodeficiency (65%), predominantly evidence of Epstein-Barr virus-driven lymphoproliferation. We investigated 66 cases of post-ALL immunodeficiency-associated lymphoid neoplasms, 52 from our study and 14 additional cases from a literature search. With a median follow-up of 4.9 years, the 5-year overall survival for the 66 patients with immunodeficiency-associated lymphoid neoplasms was 67.4% (95% confidence interval [CI], 56-81). Five-year cumulative risks of lymphoid neoplasm- and leukemia-related mortality were 20% (95% CI, 10.2-30) and 12.4% (95% CI, 2.7-22), respectively. Concurrent hemophagocytic lymphohistiocytosis was associated with increased mortality (hazard ratio, 7.32; 95% CI, 1.62-32.98; P =.01). A large proportion of post-ALL lymphoid neoplasms are associated with an immunodeficient state, likely precipitated by ALL maintenance therapy. Awareness of this underrecognized entity and pertinent diagnostic tests are crucial for early diagnosis and optimal therapy.

Návaznosti

MUNI/A/1395/2022, interní kód MU

Název: Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“

Investor: Masarykova univerzita, Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“

Citovat

ELITZUR, Sarah, Ajay VORA, Birgit BURKHARDT, Hiroto INABA, Andishe ATTARBASCHI, Andre BARUCHEL, Gabriele ESCHERICH, Brenda GIBSON, Hsi-Che LIU, Mignon LOH, V Moorman ANTHONY, Anja MOERICKE, Rob PIETERS, Anne UYTTEBROECK, Susan BAIRD, Jack BARTRAM, Shlomit BARZILAI-BIRENBOIM, Sandeep BATRA, Miriam BEN-HAROSH, Yves BERTRAND, Trudy BUITENKAMP, Kenneth CALDWELL, Ricardo DRUT, Ashley V GEERLINKS, Gil GILAD, John GRAINGER, Stephanie HAOUY, Nicholas HEANEY, Mary HUANG, Danielle INGHAM, Zdenka KŘENOVÁ, Michaela KUHLEN, Thomas LEHRNBECHER, Atsushi MANABE, Felix NIGGLI, Claudia PARIS, Shoshana REVEL-VILK, Pierre ROHRLICH, Mohamad G SINNO, Tomasz SZCZEPANSKI, Melanie TAMESBERGER, Rajasekharan WARRIER, Matthias WOLFL, Ronit NIREL, Shai IZRAELI, Arndt BORKHARDT a Kjeld SCHMIEGELOW. EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy. Blood. Washington DC, USA: American Society of Hematology, 2023, roč. 141, č. 7, s. 743-755. ISSN 0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood.2022016975.

@article{2293058,
   author = {Elitzur, Sarah and Vora, Ajay and Burkhardt, Birgit and Inaba, Hiroto and Attarbaschi, Andishe and Baruchel, Andre and Escherich, Gabriele and Gibson, Brenda and Liu, HsiandChe and Loh, Mignon and Anthony, V Moorman and Moericke, Anja and Pieters, Rob and Uyttebroeck, Anne and Baird, Susan and Bartram, Jack and BarzilaiandBirenboim, Shlomit and Batra, Sandeep and BenandHarosh, Miriam and Bertrand, Yves and Buitenkamp, Trudy and Caldwell, Kenneth and Drut, Ricardo and Geerlinks, Ashley V and Gilad, Gil and Grainger, John and Haouy, Stephanie and Heaney, Nicholas and Huang, Mary and Ingham, Danielle and Křenová, Zdenka and Kuhlen, Michaela and Lehrnbecher, Thomas and Manabe, Atsushi and Niggli, Felix and Paris, Claudia and RevelandVilk, Shoshana and Rohrlich, Pierre and Sinno, Mohamad G and Szczepanski, Tomasz and Tamesberger, Melanie and Warrier, Rajasekharan and Wolfl, Matthias and Nirel, Ronit and Izraeli, Shai and Borkhardt, Arndt and Schmiegelow, Kjeld},
   article_location = {Washington DC, USA},
   article_number = {7},
   doi = {http://dx.doi.org/10.1182/blood.2022016975},
   keywords = {EBV-driven lymphoid neoplasms; pediatric ALL; maintenance therapy},
   language = {eng},
   issn = {0006-4971},
   journal = {Blood},
   title = {EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy},
   url = {https://ashpublications.org/blood/article-abstract/141/7/743/487024/EBV-driven-lymphoid-neoplasms-associated-with?redirectedFrom=fulltext},
   volume = {141},
   year = {2023}
}

TY  - JOUR
ID  - 2293058
AU  - Elitzur, Sarah - Vora, Ajay - Burkhardt, Birgit - Inaba, Hiroto - Attarbaschi, Andishe - Baruchel, Andre - Escherich, Gabriele - Gibson, Brenda - Liu, Hsi-Che - Loh, Mignon - Anthony, V Moorman - Moericke, Anja - Pieters, Rob - Uyttebroeck, Anne - Baird, Susan - Bartram, Jack - Barzilai-Birenboim, Shlomit - Batra, Sandeep - Ben-Harosh, Miriam - Bertrand, Yves - Buitenkamp, Trudy - Caldwell, Kenneth - Drut, Ricardo - Geerlinks, Ashley V - Gilad, Gil - Grainger, John - Haouy, Stephanie - Heaney, Nicholas - Huang, Mary - Ingham, Danielle - Křenová, Zdenka - Kuhlen, Michaela - Lehrnbecher, Thomas - Manabe, Atsushi - Niggli, Felix - Paris, Claudia - Revel-Vilk, Shoshana - Rohrlich, Pierre - Sinno, Mohamad G - Szczepanski, Tomasz - Tamesberger, Melanie - Warrier, Rajasekharan - Wolfl, Matthias - Nirel, Ronit - Izraeli, Shai - Borkhardt, Arndt - Schmiegelow, Kjeld
PY  - 2023
TI  - EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy
JF  - Blood
VL  - 141
IS  - 7
SP  - 743-755
EP  - 743-755
PB  - American Society of Hematology
SN  - 00064971
KW  - EBV-driven lymphoid neoplasms
KW  - pediatric ALL
KW  - maintenance therapy
UR  - https://ashpublications.org/blood/article-abstract/141/7/743/487024/EBV-driven-lymphoid-neoplasms-associated-with?redirectedFrom=fulltext
N2  - The development of a second malignancy after the diagnosis of childhood acute lymphoblastic leukemia (ALL) is a rare event. Certain second malignancies have been linked with specific elements of leukemia therapy, yet the etiology of most second neoplasms remains obscure and their optimal management strategies are unclear. This is a first comprehensive report of non-Hodgkin lymphomas (NHLs) following pediatric ALL therapy, excluding stem-cell transplantation. We analyzed data of patients who developed NHL following ALL diagnosis and were enrolled in 12 collaborative pediatric ALL trials between 1980-2018. Eighty-five patients developed NHL, with mature B-cell lymphoproliferations as the dominant subtype (56 of 85 cases). Forty-six of these 56 cases (82%) occurred during or within 6 months of maintenance therapy. The majority exhibited histopathological characteristics associated with immunodeficiency (65%), predominantly evidence of Epstein-Barr virus-driven lymphoproliferation. We investigated 66 cases of post-ALL immunodeficiency-associated lymphoid neoplasms, 52 from our study and 14 additional cases from a literature search. With a median follow-up of 4.9 years, the 5-year overall survival for the 66 patients with immunodeficiency-associated lymphoid neoplasms was 67.4% (95% confidence interval [CI], 56-81). Five-year cumulative risks of lymphoid neoplasm- and leukemia-related mortality were 20% (95% CI, 10.2-30) and 12.4% (95% CI, 2.7-22), respectively. Concurrent hemophagocytic lymphohistiocytosis was associated with increased mortality (hazard ratio, 7.32; 95% CI, 1.62-32.98; P =.01). A large proportion of post-ALL lymphoid neoplasms are associated with an immunodeficient state, likely precipitated by ALL maintenance therapy. Awareness of this underrecognized entity and pertinent diagnostic tests are crucial for early diagnosis and optimal therapy.
ER  -

ELITZUR, Sarah, Ajay VORA, Birgit BURKHARDT, Hiroto INABA, Andishe ATTARBASCHI, Andre BARUCHEL, Gabriele ESCHERICH, Brenda GIBSON, Hsi-Che LIU, Mignon LOH, V Moorman ANTHONY, Anja MOERICKE, Rob PIETERS, Anne UYTTEBROECK, Susan BAIRD, Jack BARTRAM, Shlomit BARZILAI-BIRENBOIM, Sandeep BATRA, Miriam BEN-HAROSH, Yves BERTRAND, Trudy BUITENKAMP, Kenneth CALDWELL, Ricardo DRUT, Ashley V GEERLINKS, Gil GILAD, John GRAINGER, Stephanie HAOUY, Nicholas HEANEY, Mary HUANG, Danielle INGHAM, Zdenka KŘENOVÁ, Michaela KUHLEN, Thomas LEHRNBECHER, Atsushi MANABE, Felix NIGGLI, Claudia PARIS, Shoshana REVEL-VILK, Pierre ROHRLICH, Mohamad G SINNO, Tomasz SZCZEPANSKI, Melanie TAMESBERGER, Rajasekharan WARRIER, Matthias WOLFL, Ronit NIREL, Shai IZRAELI, Arndt BORKHARDT a Kjeld SCHMIEGELOW. EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy. \textit{Blood}. Washington DC, USA: American Society of Hematology, 2023, roč.~141, č.~7, s.~743-755. ISSN~0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood.2022016975.

Podrobný výpis o publikaci